Articles from Nocion Therapeutics, Inc.

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that it will be presenting a poster at the European Respiratory Society (ERS) 2026 Cough Conference taking place from July 15-17, 2026, in London.

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced the appointment of Vineet Agarwal, MBA as Chief Business Officer.

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that its Phase 2b ASPIRE trial evaluating taplucainium for the treatment of refractory or unexplained chronic cough (rCC/uCC) is fully enrolled.

Nocion Therapeutics, Inc., a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced the expansion of its Board of Directors with the appointment of Mark Iwicki, a recognized leader in building and maximizing value in biopharmaceutical companies, including through successful strategic transactions.

Nocion Therapeutics, Inc. a biopharmaceutical company developing novel small molecule therapies that selectively silence activated sensory neurons, today announced that preclinical data supporting the potential use of its proprietary charged sodium channel blockers, known as nocions™, for the treatment of certain types of pain will be presented at the Non-Opioid Pain Therapeutics Summit, taking place January 27-29, 2026 in Boston, MA.

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount of the Series B financing to $93 million. The financing extends the Company’s operating runway through 2027, beyond the expected topline results from Nocion’s ASPIRE Phase 2b clinical trial of taplucainium in adults with refractory or unexplained chronic cough (rCC/uCC), which are expected in mid-2026.

Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced that it had appointed Matthew Frankel, M.D., MBA as Chief Medical Officer.

Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively silence actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced that the first patient has been dosed in the Phase 2b ASPIRE clinical trial of taplucainium for the treatment of chronic cough.

Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced the presentation of progress in the development of taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium. The presentation and poster will be given by Bernard Silverman, MD., Nocion’s Chief Medical Officer.

Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that selectively silence actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain, today announced that it had appointed Dr. Catherine Bonuccelli to its Scientific Advisory Board and Joan Shaw to Senior Vice President, Clinical Operations. Both Bonuccelli and Shaw held leadership roles in the successful clinical development of camlipixant for persistent cough as members of the Bellus Health clinical team.